BrainsGate
Innovative medical device enhancing brain blood flow to treat ischemic stroke within 24 hours of symptom onset.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
$14.0m Valuation: $147m | Series F | ||
| Total Funding | 000k | ||
Related Content
BrainsGate is a medical device company specializing in the development of a novel treatment modality known as electrical SPG stimulation. This technology is designed to increase blood flow to the brain, offering significant potential for treating central nervous system disorders. The company's primary focus is on improving outcomes for patients suffering from ischemic stroke, particularly within a critical 24-hour window after the onset of symptoms.
BrainsGate operates in the healthcare and medical device market, targeting hospitals, clinics, and healthcare providers who treat stroke patients. The business model revolves around the development, clinical testing, and eventual commercialization of its proprietary technology. Revenue is generated through the sale of medical devices and potentially through licensing agreements with healthcare institutions and other medical device companies.
Keywords: medical device, ischemic stroke, SPG stimulation, brain blood flow, central nervous system, healthcare, hospitals, clinics, treatment modality, commercialization.